IPH4502 is a novel and differentiated topoisomerase I inhibitor ADC designed to precisely target Nectin-4, a cell adhesion ...

Toripalimab, independently developed by Junshi Biosciences, is a monoclonal antibody targeting PD-1 for the treatment of ...

General Manager and CEO of Junshi Biosciences, Dr. Jianjun ZOU, said, "Toripalimab has made significant strides in its ...

A Keighley deli owner is taking part in clinical trials of a new drug which could transform bladder cancer treatment.

A KEIGHLEY deli owner is taking part in clinical trials of a new drug which could transform bladder cancer treatment.

UroGen Pharma Ltd., a pioneering pharmaceutical company with a focus on innovative treatments for urothelial cancers, recently submitted an 8-K form to the Securities and Exchange Commission, ...

Patients with a common aggressive type of bladder cancer could get correct treatment significantly quicker as new research suggests that initial MRI imaging and biopsy could be used to reduce the time ...

BladderPath trial found that patients with suspected invasive bladder cancer undergoing initial mpMRI were treated faster ...

Japanese drugmaker Daiichi Sankyo announced that it will pay Glycotope GmbH $132.5 million to acquire intellectual property ...

Daiichi Sankyo has finalised the acquisition of intellectual property rights for gatipotuzumab, an anti-tumour-associated ...

Biopharma executives were busy Monday, striking high-value deals and providing updates on cancer, obesity and vaccine ...